Find participating medical centers and current study status in each of them
-
Home
-
Clinical Study Finder
- ZUPREME-5
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
-
Metabolic Disorder -
Obesity -
Cardiovascular Disorder -
Cardiovascular Disease
- For Medical Professional
-
Download -
Basic Details
Study Summary
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).
Eligibility Criteria
Inclusion Criteria
- Participants with BMI ≥ 27 kg/m² and established CVD
- History of at least one self-reported unsuccessful dietary effort to lose body weight
Exclusion Criteria
- Known history of Type 1 diabetes mellitus
- Current or previous treatment with petrelintide or any other amylin analog
This page summarises information from public registry websites, such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. To learn more about this study, see the For Medical Professional tab or visit one of those websites.
The clinical trial information herein is sourced from public registries such as ClinicalTrials.gov, EuClinicalTrials.eu, and ISRCTN.com. Additional patient-friendly (lay) content has been prepared by Roche to support understanding.
Results Disclaimer
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com